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Introduction 
Squamous cell carcinoma (SCC) 
comprises about 1.2 - 4.5% of all vesical 
tumors in the United States.1 In contrast, it 
comprises almost 75% of all bladder cancers 
in areas endemic of Shistosoma 
haemotobium.  In non-bilharzial regions of 
the world, SCC involves chronic irritation, 
such as prolonged indwelling Foley 
catheters and chronic urinary tract 
infections, which confers up to 28-fold 
increased risk for SCC.2 There are previous 
reports of humoral hypercalcemia and 
paraproteinemia associated with bladder 
cancers, but not simultaneously.3-7 
We report the first known case of 
squamous cell carcinoma of the bladder with 
paraproteinemia and symptomatic hyper-
calcemia. We also review the literature on 
humoral hypercalcemia. 
 
Case Report 
A 54-year-old African-American female 
presented with complaints of weakness, 
urinary retention, and fever of 
approximately one-week duration.  She had 
a history of multiple sclerosis with a chronic 
indwelling Foley catheter secondary to a 
neurogenic bladder.  The initial examination 
in the emergency department showed an 
obstructed Foley catheter that when 
replaced, five mL of grossly bloody urine 
was returned.  
The initial labs were significant for a 
creatinine of 15 mg/dL, BUN of 125 mg/dL, 
potassium of 5.7 mmol/mL, white blood cell  
 
count of 12900 cells/mm3, and hemoglobin 
of 8.5 mg/dL.  Iron studies were consistent 
with anemia of chronic disease. 
A computed tomography of the pelvis 
showed bilateral severe hydro-nephrosis 
with circumferential thickening of the 
bladder wall. The patient was started on 
dialysis. Bilateral ureteral tubes failed to 
relieve the obstruction.  Nephrostomy was 
necessary to drain the kidneys. After initial 
stabilization, cytoscopy was performed and 
a bladder tumor was identified. Pathology 
revealed a moderately differentiated 
squamous cell carcinoma with focal necrosis 
and invasion into the muscle wall.  
During the hospital course, the patient 
had multiple electrolyte abnormalities that 
were corrected.  However, she had persistent 
increased serum protein and symptomatic 
hypercalcemia of 12.0 mmol/mL that was 
unresponsive to intravenous hydration and 
loop diuretic therapy. The hypercalcemia 
was controlled by pamidronate.  
Parathyroid hormone (PTH) and vitamin 
D were low. Serum and urine immuno-
electrophoresis showed a monoclonal peak 
of 153 mg/dl of immunoglobulin Kappa 
light chain confirming paraproteinemia and 
a clinical picture suggestive of multiple 
myeloma. However, the bone marrow 
biopsy showed only 1% plasma cells. A 
skeletal survey and bone scan were negative.  
The diagnosis of monoclonal gammopathy 
of  undetermined  significance (MGUS) was  
made.   Later,   lab   results   for  parathyroid  
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hormone-related peptide (PTH-rP) were 
found to be elevated, confirming the 
diagnosis of humoral hypercalcemia 
secondary to a paraneoplastic syndrome of 
the bladder tumor.  
Ultimately, the patient was stabilized for 
surgery and underwent cystectomy, 
hysterectomy with bilateral oophorectomy, 
and bladder reconstruction. She had severe 
adhesions in her abdomen and metastatic 
disease in her peritoneal cavity.  Her PTH-rp 
level dropped to normal after surgery.  The 
patient declined transfer to a skilled nursing 
home and was discharged home against 
medical advice.  
 
Discussion 
The pathophysiology of hypercalcemia 
of malignancy is most commonly the result 
of two mechanisms, osteolytic and 
humoral.8  Osteolytic hypercalcemia occurs 
by invasion of the tumor into the bone, 
either by direct invasion or metastatic 
disease, commonly seen in breast cancer, 
lymphoma, and multiple myeloma.9 
Interestingly, myeloma cells activate genes 
that result in a dysregulation of normal bone 
homeostasis, resulting in simultaneous 
stimulation of bone resorption and inhibition 
of bone formation.10  
Humoral hypercalcemia of malignancy 
(HHM), first suggested by Albright in 
1941,11 is most commonly due to the 
secretion of parathyroid hormone–related 
peptide (PTH-rP) and less commonly a 
result of secretion of the active form of 
vitamin D, 1,25-dihydroxyvitamin D.3  It is 
commonly seen in squamous cell carcinoma 
of the lung, renal cancer, ovarian cancer, and 
endometrial cancer.9  PTH-rP, genetically 
different than the native variant, is a peptide 
that binds to the PTH receptor and 
stimulates osteoclastic bone resorption 
causing hypercalcemia. 
The work-up for metastatic bone disease 
and multiple myeloma were negative.  This 
finding is still significant since para-
proteinemia, such as MGUS, are associated 
to solid tumor and are able to bind calcium, 
causing hypercalcemia.7,12 Thus, the 
patient’s hypercalcemia could be due to 
either HHM, a non-calcium-binding 
mechanism or paraproteinemia, which can 
be calcium-binding. The distinction was 
necessary since therapy is not indicated in 
the latter. 
Hypercalcemia secondary to a calcium-
binding paraprotein would be expected to be 
asymptomatic.  The ionized calcium would 
be expected to be within normal limits. 
Treatment of hypercalcemia does not affect 
survival, but is necessary to prevent the 
complications of hypercalcemia in the 
interim before surgery.9 
Our patient had increased ionized 
calcium along with a finding of PTH-rP, 
confirming HHM and ruling out a calcium-
binding paraproteinemia.  Even though one 
study7 suggested that paraproteinemia may 
be as high as 1.1% in patients with solid 
tumors, to our knowledge, this is the first 
report of a patient with HHM with the 
etiology of the elevated calcium being 
confounded by paraproteinemia. 
Humoral hypercalcemia of malignancy 
is not uncommon and is well documented in 
squamous cell carcinomas of the esophagus, 
cervix, and lung, but is rarely documented in 
squamous cell carcinoma of the bladder.  
There have been prior reports of humoral 
hypercalcemia of malignancy in squamous 
cell carcinoma of the bladder, but to our 
knowledge this is the first reported case of 
hypercalcemia of squamous cell carcinoma 
of the bladder with an associated 
paraproteinemia. 
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